Document is current

Article History

Accepted: 17 June 2024

First Online: 27 June 2024

Declarations

:

: This work was not supported by any specific funding.

: Annegret Dahlmann-Noor is/has been the principal investigator on myopia intervention trials (sponsors: Nevakar, NIHR, Ocumension, DopaVision) and has received speaker/advisor fees from Santen, Thea, Novartis, CooperVision, SightGlassVision, and Zeiss, for taking part in educational events and/or advisory boards. Kanwal Nischal is a principal investigator on myopia intervention trials (sponsors: Essilor, Ocumension). Dominique Bremond-Gignac has received speaker/advisor fees from Alcon, Bausch&Lomb, CooperVision, Essilor, J&J/Janssen, Hoya, Krys, Santen, Thea, and Zeiss, for taking part in educational events and/or advisory boards. Jill Bloom, Saw Keng Lee, and Samiya Chowdhury have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

: Not applicable.

: ADN conceptualized this article and produced the first draft. JB, SKL, and SC carried out substantial searches of the use of commercial and compounded eye preparations in children in the UK, DBG carried out the same review in France, and KN in the USA. JB, SKL, SC, and KN then wrote the relevant sections. JB, SKL, SC, and KN also wrote sections on the background of compounding preparations and contributed relevant references. All authors critically reviewed and improved earlier and interim drafts of the manuscript. All authors have given approval of the final version of this manuscript, and have agreed to be accountable for all aspects of the work.